(2020). Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP).
Chicago Style (17th ed.) CitationImmunotherapy at Any Line of Treatment Improves Survival in Patients with Advanced Metastatic Non‐small Cell Lung Cancer (NSCLC) Compared with Chemotherapy (Quijote‐CLICaP). 2020.
MLA (8th ed.) CitationImmunotherapy at Any Line of Treatment Improves Survival in Patients with Advanced Metastatic Non‐small Cell Lung Cancer (NSCLC) Compared with Chemotherapy (Quijote‐CLICaP). 2020.
Warning: These citations may not always be 100% accurate.